These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22068250)

  • 21. Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance.
    Smith-Marsh D
    Drugs Today (Barc); 2013 Aug; 49(8):499-507. PubMed ID: 23977667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
    Kelly AS; Bergenstal RM; Gonzalez-Campoy JM; Katz H; Bank AJ
    Cardiovasc Diabetol; 2012 Jun; 11():64. PubMed ID: 22681705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
    Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone.
    DeFronzo RA; Tripathy D; Abdul-Ghani M; Musi N; Gastaldelli A
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3774-81. PubMed ID: 24937535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test.
    Retnakaran R; Shen S; Hanley AJ; Vuksan V; Hamilton JK; Zinman B
    Obesity (Silver Spring); 2008 Aug; 16(8):1901-7. PubMed ID: 18551118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study.
    Bianchi C; Miccoli R; Trombetta M; Giorgino F; Frontoni S; Faloia E; Marchesini G; Dolci MA; Cavalot F; Cavallo G; Leonetti F; Bonadonna RC; Del Prato S;
    J Clin Endocrinol Metab; 2013 May; 98(5):2100-5. PubMed ID: 23539736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
    Ceriello A; Johns D; Widel M; Eckland DJ; Gilmore KJ; Tan MH
    Diabetes Care; 2005 Feb; 28(2):266-72. PubMed ID: 15677777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes.
    Luo Y; Paul SK; Zhou X; Chang C; Chen W; Guo X; Yang J; Ji L; Wang H
    J Diabetes Res; 2017; 2017():7602408. PubMed ID: 28168204
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes.
    Rasouli N; Kern PA; Reece EA; Elbein SC
    Am J Physiol Endocrinol Metab; 2007 Jan; 292(1):E359-65. PubMed ID: 16968813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of insulin resistance and β cell function in the development of newly diagnosed type 2 diabetes].
    Chen X; Su M; Wang C; Wu Z; Li S; Ying X; Wei G; Fu C; Jiang Q
    Wei Sheng Yan Jiu; 2015 Nov; 44(6):881-6. PubMed ID: 26738376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
    Tao T; Zhang Y; Zhu YC; Fu JR; Wang YY; Cai J; Ma JY; Xu Y; Gao YN; Sun Y; Fan W; Liu W
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1420-e1432. PubMed ID: 32995892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
    Santilli F; Simeone PG; Guagnano MT; Leo M; Maccarone MT; Di Castelnuovo A; Sborgia C; Bonadonna RC; Angelucci E; Federico V; Cianfarani S; Manzoli L; Davì G; Tartaro A; Consoli A
    Diabetes Care; 2017 Nov; 40(11):1556-1564. PubMed ID: 28912305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats.
    Choi SH; Zhao ZS; Lee YJ; Kim SK; Kim DJ; Ahn CW; Lim SK; Lee HC; Cha BS
    Diabetes Metab Res Rev; 2007 Jul; 23(5):411-8. PubMed ID: 17538941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
    Nauck MA; Meier JJ
    Nat Rev Endocrinol; 2011 Apr; 7(4):193-5. PubMed ID: 21326278
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.
    Rosenstock J; Klaff LJ; Schwartz S; Northrup J; Holcombe JH; Wilhelm K; Trautmann M
    Diabetes Care; 2010 Jun; 33(6):1173-5. PubMed ID: 20332357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and treatment of prediabetes to prevent progression to type 2 diabetes.
    Fonseca VA
    Clin Cornerstone; 2007; 8(2):10-8; discussion 19-20. PubMed ID: 18357952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
    Samson SL; Sathyanarayana P; Jogi M; Gonzalez EV; Gutierrez A; Krishnamurthy R; Muthupillai R; Chan L; Bajaj M
    Diabetologia; 2011 Dec; 54(12):3093-100. PubMed ID: 21956711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.